Natera, Inc. (NASDAQ:NTRA) CFO Sells $53,592.60 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 499 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $107.40, for a total transaction of $53,592.60. Following the transaction, the chief financial officer now directly owns 77,418 shares of the company’s stock, valued at $8,314,693.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, July 1st, Michael Burkes Brophy sold 4,983 shares of Natera stock. The shares were sold at an average price of $108.37, for a total transaction of $540,007.71.
• On Wednesday, May 1st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $93.97, for a total transaction of $175,348.02.
• On Monday, April 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $93.14, for a total transaction of $115,307.32.
• On Thursday, April 25th, Michael Burkes Brophy sold 705 shares of Natera stock. The stock was sold at an average price of $89.55, for a total transaction of $63,132.75.

Natera Stock Performance

Shares of NTRA opened at $102.15 on Friday. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $117.23. The company has a 50-day moving average of $109.26 and a 200 day moving average of $91.99. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.16. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The company had revenue of $367.70 million during the quarter, compared to analyst estimates of $316.31 million. During the same quarter last year, the business posted ($1.23) EPS. The firm’s revenue for the quarter was up 52.1% on a year-over-year basis. As a group, research analysts anticipate that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTRA. Assenagon Asset Management S.A. raised its holdings in shares of Natera by 291.2% in the 4th quarter. Assenagon Asset Management S.A. now owns 423,080 shares of the medical research company’s stock valued at $26,502,000 after purchasing an additional 314,935 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Natera by 3.0% in the 4th quarter. Fifth Third Bancorp now owns 6,216 shares of the medical research company’s stock valued at $389,000 after purchasing an additional 179 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Natera by 1.9% in the 4th quarter. Arizona State Retirement System now owns 31,497 shares of the medical research company’s stock valued at $1,973,000 after purchasing an additional 579 shares in the last quarter. International Assets Investment Management LLC raised its holdings in shares of Natera by 6,007.5% in the 4th quarter. International Assets Investment Management LLC now owns 7,329 shares of the medical research company’s stock valued at $459,000 after purchasing an additional 7,209 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Natera by 28.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock valued at $45,111,000 after purchasing an additional 159,993 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on NTRA shares. Canaccord Genuity Group lifted their price objective on shares of Natera from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday, May 10th. The Goldman Sachs Group lifted their price objective on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective for the company in a research note on Friday, April 5th. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research note on Friday, May 17th. Finally, BTIG Research lifted their price objective on shares of Natera from $100.00 to $125.00 and gave the stock a “buy” rating in a research note on Monday, May 13th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.19.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.